Clinical Trial
Response rate and toxicity of etoposide (VP-16) in squamous carcinoma of the lung: report from the Lung Cancer Treatment Study Group
- PMID: 3883504
Item in Clipboard
Clinical Trial
Response rate and toxicity of etoposide (VP-16) in squamous carcinoma of the lung: report from the Lung Cancer Treatment Study Group
Semin Oncol.
1985 Mar.
Abstract
In two multicenter studies, 325 patients with advanced squamous lung cancer were randomized to receive either no treatment v oral etoposide (VePe-sid) 300 mg/m2 on days 1 and 2 for 6 cycles, or the same dose of oral etoposide v the same dose of oral etoposide plus cyclophosphamide 300 mg/m2 IV on days 1 and 2, each given for 6 cycles. A total of 175 patients in both trials received oral etoposide alone. All patients assigned to treatment were included in the results. Remissions occurred in 20 (11%) patients (CR in 1; PR in 19). Leukopenia occurred in 2% of patients and other toxicity was acceptable.
Similar articles
-
[A phase II study of etoposide (VP-16) injection in primary lung cancer by cooperative study group].Gan To Kagaku Ryoho. 1986 Jan;13(1):116-21. Gan To Kagaku Ryoho. 1986. PMID: 3002282 Japanese.
-
[A phase II study of NK171 (etoposide)].Gan To Kagaku Ryoho. 1985 Oct;12(10):2011-7. Gan To Kagaku Ryoho. 1985. PMID: 2996442 Japanese.
-
[A phase II study of oral VP-16 in primary lung cancer].Gan To Kagaku Ryoho. 1985 Sep;12(9):1801-7. Gan To Kagaku Ryoho. 1985. PMID: 2994576 Japanese.
-
Etoposide (VP-16) in the treatment of lung cancer.Cancer Treat Rev. 1983 Dec;10(4):245-64. doi: 10.1016/0305-7372(83)90013-0. Cancer Treat Rev. 1983. PMID: 6318994 Review. No abstract available.
-
Etoposide (VP-16-213). Current status of an active anticancer drug.N Engl J Med. 1985 Mar 14;312(11):692-700. doi: 10.1056/NEJM198503143121106. N Engl J Med. 1985. PMID: 2983208 Review. No abstract available.
Cited by
-
Chemotherapy for non-small cell lung cancer.Cochrane Database Syst Rev. 2000;2000(2):CD002139. doi: 10.1002/14651858.CD002139. Cochrane Database Syst Rev. 2000. PMID: 10796867 Free PMC article.
-
Effect of fluosol-DA/carbogen on etoposide/alkylating agent antitumor activity.Cancer Chemother Pharmacol. 1988;21(4):281-5. doi: 10.1007/BF00264192. Cancer Chemother Pharmacol. 1988. PMID: 3131032
-
Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group.BMJ. 1995 Oct 7;311(7010):899-909. BMJ. 1995. PMID: 7580546 Free PMC article.
-
Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials.J Clin Oncol. 2008 Oct 1;26(28):4617-25. doi: 10.1200/JCO.2008.17.7162. Epub 2008 Aug 4. J Clin Oncol. 2008. PMID: 18678835 Free PMC article.
-
Best first-line therapy for people with advanced non-small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status.Cochrane Database Syst Rev. 2023 Jul 7;7(7):CD013382. doi: 10.1002/14651858.CD013382.pub2. Cochrane Database Syst Rev. 2023. PMID: 37419867 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials